|
Nanotechnology Colloquium
|
Colloquium Date: Monday, December 08, 2008
|
A bi-weekly event to present and discuss issues related to developments, applications and commercialization of nanotechnology.
"The Future of Medical Care: Personalized Medicine through Genomics, Nanotechnology and other Innovations"
Arthur P. Bollon, Ph.D.
Chairman and CEO
HemoBioTech, Inc.
(VIDEO CONFERENCED FROM DALLAS)
Abstract:
The future of medical care will be addressed by considering components of the healthcare system:
- The cost of healthcare and drugs
- Bio-Medical Technology present and future
- Innovation pathways for diagnosis and treatment
- Socio-political infrastructure
- Implementation
Attention will be given to innovation pathways through natural products, genomics, systems biology; diagnostics and nanotechnology. Implementation will focus on the stoichiometry of cost and outcome
HemoBioTech, Inc.
Hemobiotech, Inc. has the exclusive rights to HemoTech which could be the first viable hemoglobin based blood substitute which is non-toxic and also has erythropoietic activity and is anti-inflamatory. The technology is licensed from Texas Tech University Health Science Center. HemoTech is based on the novel modification of hemoglobin with ATP, Adenosine and GSH which results in vasodilation, down regulation of NF-kappa B, and induction of erythropoietin. Based on initial foreign clinical studies, HemoTech is nontoxic and increased circulating reticulocytes about ten fold after three days. All other attempts to develop a substitute for human blood have failed due to toxicities such as vasoconstriction, inflammation and oxygen stress. The global market for human blood is over $100 billion and a non-toxic substitute which also induces erythropoiesis and is not inflammatory could supplant a significant part of this market. Management and advisors are stellar, including two former US Army Surgeon Generals. In April 2008, the FDA cited the Adenosine/GSH technology of HemoTech as a viable strategy for a needed new generation hemoglobin based blood substitute.
Bio:
Arthur P. Bollon, Ph.D.
Dr. Bollon is Chairman and Chief Executive Officer of Hemobiotech. He has over twenty five years experience in biotechnology as a scientist with multiple scientific communications, entrepreneur and executive having served as Founder, Chairman and CEO of three biotechnology companies. He was Founder, Chairman and CEO of Wadley Biosciences/LPL, a limited partnership between Wadley Cancer Center and Phillips Petroleum which focused on production and development of human cytokines such as interferon and TNF. He was also Founder, Chairman, and CEO of Cytoclonal Pharmaceutics, Inc. which he brought public in 1995, raised about $65 million, established a relationship with Bristol-Meyers Squibb for production of TAXOL by microbial fermentation. He also acquired mechanism based drug design technology based on Nobel Prize work of Dr. John Pople. He has served on the faculty of University of Texas Southwestern Medical School and adjunct faculty of University of Texas at Dallas. Dr. Bollon has a Ph.D. from Rutgers University in molecular genetics and was a Postdoctoral Fellow at Yale University.
|
|
|
VENUE: You may attend the presentation from any
one of these law offices of Winstead PC or from UT Dallas
|
|
AUSTIN: Winstead PC
401 Congress Av., Ste 2100
Austin, TX 78701
512-370-2800
|
|
CHICAGO: NEW VENUE Illinois Institute of Technology
Stuart Building, Room 212, 10 West 31st Street Chicago
IL 60616; Contact Jennifer Keplinger at keplinger@iit.edu to confirm attendence
|
|
COLLEGE STATION: Texas A&M University
Wisenbaker Building (WERC), Room #049,
College Station, TX 77843;
979-845-8912
|
|
|
DALLAS: Winstead PC
5400 Renaissance Tower, 1201 Elm Street
Dallas, TX 75270; 214-745-5400
|
|
EL PASO: El Paso Community College
9050 Viscount, Bldg. B
El Paso, TX 79925
|
|
|
HOUSTON: Winstead PC
1100 JPMorgan Chase Tower
600 Travis Street
Houston, TX 77002
713-650-8400
|
|
|
SAN ANTONIO: Winstead PC
700 N. St Mary St., Ste 1900
San Antonio, TX 78205
210-277-6800
|
|
|
THE WOODLANDS: Winstead PC
600 Town Center One
1450 Lake Robbins Drive
The Woodlands, TX 77380
281-681-5900
|
|
|
Program begins at 11:30am [CDT] with a complimentary lunch provided by Winstead PC.
Presentation begins at 12:00pm.
Event Coordinators:
Richard Fink 512-339-5020x130 dfink@appliednanotech.net
Max Roundhill 512-339-5020x120 roundhill@appliednanotech.net
Chairman: Dr. Zvi Yaniv
Registration deadline is Friday, December 8 at 5:00 PM Central.
To register, please send an email to Nina Shuvalov
NShuvalov@appliednanotech.net with your preferred attendance location.
|
| |
|
|
NANOMATERIALS APPLICATION CENTER
Walt Trybula, Ph.D.
Director
Texas State University
San Marcos, TX
(512) 245-6062
|
DVDs of selected presentations from previous
speakers are available for a small fee (contact
Max Roundhill mroundhill@appliednanotech.net)
NanoExpress, a monthly email newsletter, is
devoted to providing information on technological
advances, applications, and business news to
nanotechnology professionals. To subscribe, go to
the web link
http://www.txstate.edu/nac/nanoexpress.htmlx
Return to the Schedule Page
|
|
